American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1381)
  9. Gastrointestinal Oncology Service (1356)
  10. Hematologic Malignancies, Division of (1286)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2591)
  3. Editorial (79)
  4. Review (70)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (308)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (303)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8712)
  2. JCO Precision Oncology (174)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (54)
  6. JCO Oncology Practice (12)

More Publications

Results (9195)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma
    Meeting Abstract

    Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Bedke, J.; Powles, T.; Valderrama, B. P.; Gupta, S.; Kikuchi, E.; Loriot, Y.; Galsky, M D.; Sridhar, S. S.; Yu, E. Y.; Hoffman-Censits, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype
    Meeting Abstract

    Carlo, M.; Chen, Y. B.; Knezevic, A.; Zong, G.; Bakouny, Z.; Kemel, Y.; Latham, A.; Liu, Y. L.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study
    Meeting Abstract

    Chehrazi-Raffle, A.; Motzer, Robert J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillomd, J.; Garmezy, B.; Barata, P. C.; McKay, R. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clear and non-clear cell renal cell carcinomas and the ability to engage in oxidative phosphorylation
    Meeting Abstract

    Bakouny, Z.; Boscenco, S.; Cui, R.; Ryu, K.; Kotecha, R. R.; Carlo, M.; Voss, M. H.; Hakimi, A. A.; Motzer, R. J.; Gammage, P. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Prenatal cell-free DNA sequencing and intrahepatic cholangiocarcinoma
    Journal Article

    Goldlust, I. S.; Gormally, M. V.; Teichholtz, S.; Turriff, A. E.; Harding, J. J.; Bianchi, D. W.
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Reply to: Safe outpatient treatment of CNS lymphoma achieved by using glucarpidase after high-dose methotrexate
    Correspondence

    Schaff, L. R.; Grommes, C.
    JCO Oncology Practice (2025)

    Fulltext@MSK | Save
  • Promoting reasonable career expectations and maximizing professional fulfillment for academic oncologists: ASCO recommendations for academic medical centers
    Journal Article

    Winer, E. P.; Levit, L. A.; Basch, E.; Chavez-Macgregor, M.; Dubois, R.; Eckhardt, S. G.; Ellis, L. M.; Hudis, C. A.; Schrag, D.; Speers, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML
    Journal Article

    Zeidner, J. F.; Lin, T. L.; Welkie, R. L.; Curran, E.; Koenig, K.; Stock, W.; Madanat, Y. F.; Swords, R.; Baer, M. R.; Blum, W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save